Advance Search

EFEKTIVITAS DAN EFEK SAMPING DARI IMPLAN LEVONORGESTREL DAN IMPLAN ETONOGESTREL: REVIEW ARTICLE

DOI: https://doi.org/10.20956/mff.v27i3.24910
Article History

Submited : January 5, 2023
Published : December 31, 2023

Keywords:
Implan levonorgestrel (LVN) dan etonogestrel (ENG) merupakan contoh long-acting reversible contraception (LARC) yang memiliki efektifitas yang tinggi dalam pencegahan kehamilan pada jangka waktu yang panjang. Penulisan review ini bertujuan untuk membandingkan efektifitas dan efek samping terkait LVN 2 batang dan ENG 1 batang sebagai alat kontrasepsi implan subdermal. Studi mengenai perbandingan efikasi implan LVN dengan implan ENG menunjukkan bahwa keduanya memiliki efikasi sebagai kontrasepsi yang baik diamati dari tingkat kejadian kehamilan yang sangat rendah. Perbedaan antara keduanya dapat dilihat dari berapa lama durasi yang disetujui untuk perlindungan dalam pencegahan kehamilan yaitu 3 tahun untuk implan ENG dan 5 tahun untuk implan LVN. Selain itu, Efektivitas kedua implan tersebut dalam mencegah kehamilan menunjukkan efek yang sebanding dari berbagai pengujian. Terkait studi mengenai efek samping menunjukkan bahwa efek samping pendarahan pada penggunaan ENG lebih besar dibandingkan pada implan LVN, sehingga LVN lebih dipilih dibandingkan dengan ENG.

References

  1. Bahamondes L, Fernandes A, Monteiro I, Bahamondes MV. Long-acting reversible contraceptive (LARCs) methods. Best Pract Res Clin Obstet Gynaecol. 2020 Jul;66:28–40.
  2. 2. Roberts O, Rajoli RKR, Back DJ, Owen A, Darin KM, Fletcher C V, et al. Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug–drug interactions between levonorgestrel contraceptive implans and efavirenz-based ART. J Antimicrob Chemother. 2018 Apr 1;73(4):1004–12.
  3. 3. Croxatto HB. Mechanisms that explain the contraceptive action of progestin implans for women. Contraception. 2002 Jan;65(1):21–7.
  4. 4. Peralta O, Diaz S, Croxatto H. Subdermal contraceptive implans. J Steroid Biochem Mol Biol. 1995 Jun;53(1–6):223–6.
  5. 5. Contraceptive implan - NHS [Internet]. [cited 2022 Aug 28]. Available from: https://www.nhs.uk/conditions/contraception/contraceptive-implan/
  6. 6. Rocca ML, Palumbo AR, Visconti F, Di Carlo C. Safety and Benefits of Contraceptives Implans: A Systematic Review. Pharmaceuticals. 2021 Jun 8;14(6):548.
  7. 7. Drugs and Lactation Database. Levonorgestrel Implan Drug Levels and Effects Effects in Breastfed Infants. Natl Libr Med. 2021;(Md):1–5.
  8. 8. Mishell DR. Contraception. In: Goldman’s Cecil Medicine. Elsevier; 2012. p. 1552–5.
  9. 9. Ali M, Bahamondes L, Bent Landoulsi S. Extended Effectiveness of the Etonogestrel-Releasing Contraceptive Implan and the 20 µg Levonorgestrel-Releasing Intrauterine System for 2 Years Beyond U.S. Food and Drug Administration Product Labeling. Glob Health Sci Pract. 2017;5(4):534–9.
  10. 10. Schreiber CA, Barnhart K. Contraception. In: Yen & Jaffe’s Reproductive Endocrinology. Elsevier; 2014. p. 890-908.e3.
  11. 11. Hormonal contraceptives—progestogen implans. In: Meyler’s Side Effects of Drugs. Elsevier; 2016. p. 830–5.
  12. 12. Hubacher D, Spector H, Monteith C, Chen PL, Hart C. Long-acting reversible contraceptive acceptability and unintended pregnancy among women presenting for short-acting methods: a randomized patient preference trial. Am J Obstet Gynecol. 2017 Feb;216(2):101–9.
  13. 13. Ali M, Akin A, Bahamondes L, Brache V, Habib N, Landoulsi S, et al. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implan: comparison to levonorgestrel-releasing subdermal implan. Hum Reprod. 2016 Nov;31(11):2491–8.
  14. 14. Steiner MJ, Lopez LM, Grimes DA, Cheng L, Shelton J, Trussell J, et al. Sino-implan (II) — a levonorgestrel-releasing two-rod implan: systematic review of the randomized controlled trials. Contraception. 2010 Mar;81(3):197–201.
  15. 15. Ramdhan RC, Simonds E, Wilson C, Loukas M, Oskouian RJ, Tubbs RS. Complications of Subcutaneous Contraception: A Review. Cureus. 2018 Jan 31;10(1):e2132.
  16. 16. Levonorgestrel [Internet]. [cited 2022 Sep 27]. Available from: https://go.drugbank.com/drugs/DB00367
  17. 17. Sivasankaran S, Jonnalagadda S. Advances in controlled release hormonal technologies for contraception: A review of existing devices, underlying mechanisms, and future directions. J Controlled Release. 2021 Feb;330:797–811.
  18. 18. Friend DR. Development of controlled release systems over the past 50 years in the area of contraception. J Controlled Release. 2016 Oct;240:235–41.
  19. 19. Pam V, Mutihir J, Nyango D, Shambe I, Egbodo C, Karshima J. Sociodemographic profiles and use-dynamics of Jadelle (levonorgestrel) implans in Jos, Nigeria. Niger Med J. 2016;57(6):314.
  20. 20. Glasier A. Contraception. In: Endocrinology: Adult and Pediatric. Elsevier; 2016. p. 2297-2309.e2.
  21. 21. Olsson SE, Odlind V, Johansson EDB, Sivin I. Contraception with norplant® implans and NORPLANT®-2 implans (two covered rods). Contraception. 1988 Jan;37(1):61–73.
  22. 22. Gunardi ER, Affandi B. Serum levonorgestrel concentration and cervical mucus viscosity after six months of monoplant® implanation. Med J Indones. 2014 Mar 11;25.
  23. 23. Sinoplant – Catur Dakwah [Internet]. [cited 2022 Sep 27]. Available from: https://www.caturdakwah.com/sinoplant/
  24. 24. Maddox DD, Rahman Z. Etonogestrel (Implanon), Another Treatment Option for Contraception. Pharm Ther. 2008;33(6):337.
  25. 25. Moray K V, Chaurasia H, Sachin O, Joshi B. A systematic review on clinical effectiveness, side-effect profile and meta-analysis on continuation rate of etonogestrel contraceptive implan. Reprod Health. 2021 Jan 6;18(1):4.
  26. 26. Hickey M, Kaunitz AM. Hormonal Contraception. In: Williams Textbook of Endocrinology. Elsevier; 2011. p. 661–87.
  27. 27. Etonogestrel [Internet]. [cited 2022 Sep 27]. Available from: https://go.drugbank.com/drugs/DB00294
  28. 28. Hormonal contraceptives—progestogen implans - ClinicalKey [Internet]. [cited 2022 Aug 28]. Available from: https://www.clinicalkey.com/#!/content/book/3-s2.0-B9780444537171008556
  29. 29. Vo M. Long-Acting Reversible Contraception in Adolescents. In: Reference Module in Biomedical Sciences. Elsevier; 2021.
  30. 30. Etonogestrel: Manfaat, Dosis dan Efek Samping [Internet]. [cited 2022 Sep 27]. Available from: https://aido.id/health-articles/etonogestrel/detail
  31. 31. Bhatia P, Nangia S, Aggarwal S, Tewari C. Implanon: subdermal single rod contraceptive implan. J Obstet Gynaecol India. 2011 Aug;61(4):422–5.
  32. 32. Cooling H, Pauli H. Full-term pregnancy with Implanon® in situ. J Fam Plann Reprod Health Care. 2006 Jul 1;32(3):204–204.
  33. 33. Flores JBO, Balderas ML, Bonilla MC, Vázquez-Estrada L. Clinical experience and acceptability of the etonogestrel subdermal contraceptive implan. Int J Gynecol Obstet. 2005 Sep;90(3):228–33.
  34. 34. McNicholas C, Swor E, Wan L, Peipert JF. Prolonged use of the etonogestrel implan and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration–approved duration. Am J Obstet Gynecol. 2017 Jun;216(6):586.e1-586.e6.
  35. 35. Dugré N, Choksi N, Kirkwood J. Etonogestrel implan effectiveness. Can Fam Physician Med Fam Can. 2022 Aug;68(8):594.
  36. 36. Coukell AJ, Balfour JA. Levonorgestrel subdermal implans. A review of contraceptive efficacy and acceptability. Drugs. 1998 Jun;55(6):861–87.
  37. 37. Bahamondes L, Brache V, Meirik O, Ali M, Habib N, Landoulsi S. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implans, with non-randomized matched copper-intrauterine device controls. Hum Reprod. 2015 Nov;30(11):2527–38.
  38. 38. Shoupe D, Mishell DR. Contraception. In: Women and Health. Elsevier; 2013. p. 209–34.
  39. 39. Villavicencio J, Allen RH. Unscheduled bleeding and contraceptive choice: increasing satisfaction and continuation rates. Open Access J Contracept. 2016;7:43–52.
  40. 40. Hubacher D, Lopez L, Steiner MJ, Dorflinger L. Menstrual pattern changes from levonorgestrel subdermal implans and DMPA: systematic review and evidence-based comparisons. Contraception. 2009 Aug;80(2):113–8.
  41. 41. Haslan H, Indryani I. Hubungan Penggunaan KB Implan dengan Berat Badan dan Siklus Haid Akseptor KB. J Ilm Kesehat Sandi Husada. 2020 Jun 30;11(1):347–52.
  42. 42. Bahamondes L, Brache V, Ali M, Habib N. A multicenter randomized clinical trial of etonogestrel and levonorgestrel contraceptive implans with nonrandomized copper intrauterine device controls: effect on weight variations up to 3 years after placement. Contraception. 2018 Sep;98(3):181–7.
Chabib, L., M. Pandoman febrian, Hannie Fitriani, & Uzulul Hikmah. (2023). EFEKTIVITAS DAN EFEK SAMPING DARI IMPLAN LEVONORGESTREL DAN IMPLAN ETONOGESTREL: REVIEW ARTICLE. Majalah Farmasi Dan Farmakologi, 27(3), 129-132. https://doi.org/10.20956/mff.v27i3.24910

Copyright (c) 2023 Array

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Downloads

Download data is not yet available.
Fulltext
pdf